Sunday, April 27, 2025
Home Tags Ctxr

Tag: ctxr

Citius, Leonard Mazur
2020 Watch List

Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.

Editor / Curator -
Citius
Biotech News

Wall Street Showing Love. Hepion Pharma (HEPA), Citius Pharma (CTXR) Raise...

Editor / Curator -
Citius, Biotech Stock Review
2020 Watch List

Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.

Editor / Curator -
Biotech News

Make Hay While the Sun Shines. Up 6,400%.

Editor / Curator -
Stem Cells

Heads Up! Big News on Stem Cells & Covid This Weekend.

Editor / Curator -
cITIUS
2020 Watch List

Citius (CTXR) Announces Results of Mino-Lok Study.

Editor / Curator -
Issam Radd
2020 Watch List

Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.

Editor / Curator -
Interview

Citius Pharma (CTXR) Video Presentation.

Editor / Curator -
citius pharma, biotech stock review
2020 Watch List

Investors Bet $8 Million on Citius Pharma (CTXR) $1.10, Succeeding in...

Editor / Curator -
Biotech News

Where is Citius Pharma (CTXR) in the FDA Approval Process?

Editor / Curator -
1234Page 2 of 4

Latest article

Gold prices plunge in biggest one-day drop in years. Is the record rally over?...

All News Editor / Curator -
Easing anxieties over Trump’s tariff policies and the Fed chair’s fate spark gold’s worst daily decline since 2021 Gold...

Gold Price Sets New Intraday Record Above $3,500 (WSJ)

All News Editor / Curator -
Gold hit another record Tuesday, then faded a bit in afternoon trading. The most actively traded futures contracts surged...

Gold Surges to a Record Above $3,400 as Trump threatens Fed Independence (CNBC)

All News Editor / Curator -
Gold prices broke $3,400 on Monday, hitting a new record as President Donald Trump’s threats against the...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: [email protected]
© Managed by Revelers.IO Media Group Inc.